
WE CLAIM:


1. A pharmaceutical composition in the form of a fixed dose combination tablet comprising:

a) from about 1% to about 25% w/w of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula:



;

b) from about 35% to about 45% w/w of substantially crystalline sofosbuvir having the formula:



c) from about 30% to about 40% w/w of microcrystalline cellulose;

d) from about 1% to about 5% w/w of croscarmellose sodium; and

e) from about 0.5% to about 2.5% w/w of magnesium stearate.

2. The pharmaceutical composition of claim 1 wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1 and 12.7.

3. The pharmaceutical composition of claim 1 wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1, 20.1 and 20.8.

4. The pharmaceutical composition of any one of claims 1 to 3, comprising about 40% w/w of sofosbuvir.

5. The pharmaceutical composition of one of claims 1 to 4, comprising about 20% w/w of the solid dispersion.


6. The pharmaceutical composition of any one of claims 1 to 5, comprising about 35.5% w/w of microcrystalline cellulose.

7. The pharmaceutical composition of any one of claims 1 to 6, comprising about 3% w/w of croscarmellose sodium.


8. The pharmaceutical composition of any one of claims 1 to 7, comprising about 1.5% w/w of magnesium stearate.

9. A pharmaceutical composition in the form of a fixed dose combination tablet comprising:

a) about 20% w/w of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula:


;

b) about 40% w/w of substantially crystalline sofosbuvir having the formula:


;

c) about 35.5% w/w of microcrystalline cellulose;

d) about 3% w/w of croscarmellose sodium; and


e) about 1.5% w/w of magnesium stearate.

10. The pharmaceutical composition of claim 9 wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1 and 12.7.


11. The pharmaceutical composition of claim 9 wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1, 20.1 and 20.8.

12. A pharmaceutical composition in the form of a fixed dose combination tablet comprising:

a) about 200 mg of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula:


;

b) about 400 mg of substantially crystalline sofosbuvir having the formula:


;

c) about 355 mg of microcrystalline cellulose;

d) about 30 mg of croscarmellose sodium; and

e) about 15 mg of magnesium stearate.

13. The pharmaceutical composition of claim 12 wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1 and 12.7.

14. The pharmaceutical composition of claim 12 wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at about: 6.1, 20.1 and 20.8.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the tablet comprises a film coating.

16. The pharmaceutical composition of claim 15, wherein the film coating is a polyvinylalcohol-based coating.